A review of clinical characteristics and genetic backgrounds in Alport syndrome


Alport syndrome (AS) is a progressive hereditary renal disease that is characterized by sensorineural hearing loss and ocular abnormalities. It is divided into three modes of inheritance, namely, X-linked Alport syndrome (XLAS), autosomal recessive AS (ARAS), and autosomal dominant AS (ADAS). XLAS is caused by pathogenic variants in COL4A5, while ADAS and ARAS are caused by those in COL4A3/COL4A4. Diagnosis is conventionally made pathologically, but recent advances in comprehensive genetic analysis have enabled genetic testing to be performed for the diagnosis of AS as first-line diagnosis. Because of these advances, substantial information about the genetics of AS has been obtained and the genetic background of this disease has been revealed, including genotype–phenotype correlations and mechanisms of onset in some male XLAS cases that lead to milder phenotypes of late-onset end-stage renal disease (ESRD). There is currently no radical therapy for AS and treatment is only performed to delay progression to ESRD using nephron-protective drugs. Angiotensin-converting enzyme inhibitors can remarkably delay the development of ESRD. Recently, some new drugs for this disease have entered clinical trials or been developed in laboratories. In this article, we review the diagnostic strategy, genotype–phenotype correlation, mechanisms of onset of milder phenotypes, and treatment of AS, among others.


Alport syndrome (AS) is a progressive hereditary renal disease accompanied by sensorineural hearing loss and ocular abnormalities. AS develops because of pathogenic variants in the COL4A3, COL4A4, and COL4A5 genes encoding type IV collagen α3, α4, and α5 chains, respectively [1,2,3]. These type IV collagens constitute the glomerular basement membrane (GBM). AS has been reported to develop in approximately one in 5000 people; it comprises 0.5% of newly developed end-stage renal disease (ESRD) cases in adults [4] and 12.9% in children [5]. Type IV collagen has six different α chains, α1 to α6, which construct triple helix structures in which the three chains are combined. The combination of three α-chains is organ-specific: in the GBM, cochlea basement membrane, and base of the ocular lens, the triplet α3–α4–α5 is present, while in Bowman’s capsule and skin basement membrane, it is α5–α5–α6. When an abnormality occurs in the α-chain, these triple helix structures are broken, causing nephropathy, sensorineural hearing loss, and eye lesions. AS is divided into X-linked Alport syndrome (XLAS), autosomal recessive AS (ARAS), and autosomal dominant AS (ADAS), according to its mode of inheritance. The distribution of these cases is reported to be as follows: 80% XLAS, 15% ARAS, and 5% ADAS. XLAS is caused by abnormality of COL4A5, while ADAS and ARAS are caused by abnormality in COL4A3 or COL4A4 [3].

Clinical characteristics and diagnostic features

Table 1 shows the diagnostic features established by the members of the Working Group for Alport Syndrome in the Japanese Society of Pediatric Nephrology (JSPN) in 2015 [6]. The main criterion is persistent hematuria. When patients fulfill one or more secondary features, or two or more accessory features, in addition to the primary feature, they can be diagnosed with AS. Symptoms differ depending on the mode of inheritance, with their features described below.

Table 1 Diagnostic features of Alport syndrome (revised in February 2015) prepared by the Working Group on Alport Syndrome of the Japanese Society of Pediatric Nephrology
  1. 1)


In XLAS, there is often a family history of hematuria (with or without proteinuria) or renal failure. However, in approximately 15% of cases, there are de novo variants without a family history [3]. Microscopic hematuria is observed in all male cases. In female patients, it is observed in approximately 98% with hematuria and 73% with both hematuria and proteinuria [7]. In male patients, proteinuria is recognized at an early stage of childhood, sometimes exhibiting a nephrotic status; it is also reported that 90% of patients develop ESRD by the age of 40 years, with the median age of development of ESRD being 25 years [8]. In females, 12% of cases have developed ESRD by the age of 40 [9]. We recently reported that patients exhibited proteinuria at a median age of 7 years, and that ESRD development occurred at a median of 65 years in female XLAS [7].

Sensorineural hearing loss often occurs from the latter stage of childhood; 90% of male patients and approximately 12% of female patients present with hearing loss by the age of 40 years [8, 9]. Jais et al. reported that, in females, the presence of hearing loss predicts the development of ESRD; however, our recent study showed no significant difference in kidney severity between patients with and without hearing loss [7, 9]. Specific ocular abnormalities, including anterior lenticonus, posterior subcapsular cataract, posterior polymorphous dystrophy, and retinal flecks, are known as ophthalmologic complications; clinical symptoms, such as obvious visual impairment, rarely appear [10]. Other complications include leiomyoma due to contiguous gene deletion encompassing the 5′ end of COL4A5 and COL4A6 intron 2. In this phenotype, leiomyoma is observed with full penetration, for which no gender difference is observed [11].

  1. 2)


Clinically, ARAS shows symptoms similar to those in male XLAS patients. There are no gender differences in clinical symptoms and incidence, and this condition sporadically occurs in one generation. Families with monoallelic variant carriers are often asymptomatic or show only microscopic hematuria (and mild proteinuria) [12, 13]. For the genetic diagnosis of ARAS, analysis of at least one familial member (ideally, both parents) is necessary to prove that two heterozygous variants are located in trans positions on two different alleles (either COL4A3 or COL4A4). In terms of the clinical findings that we previously reported, the median age of ESRD development is 21 years. Sensorineural deafness was observed at a median age of onset of 20 years [12].

  1. 3)


Recently, we published an article regarding the clinical picture, pathology, and genetic background of ADAS [14]. The median age for detecting proteinuria was 17.0 years, and that for developing renal insufficiency was 70 years. In addition, both hearing loss and eye lesion were reported to occur quite rarely. Moreover, three of 16 patients with pathological findings showed focal segmental glomerular sclerosis (FSGS), as revealed by light microscopy. It has also been reported that, in approximately 10% of patients with familial focal segmental glomerulosclerosis, COL4A3 or COL4A4 mutations are identified, suggesting that there are many undiagnosed ADAS patients [15].

Pathological findings

There are no specific light microscopic findings in AS; nonspecific findings are observed, such as mesangial proliferation, FSGS, renal tubular atrophy, foam cell formation, or interstitial fibrosis. Electron microscopic (EM) findings show irregular thickening and thinning of the GBM, and lamellation and splitting in lamina densa can be observed (Fig. 1). These findings are specific to AS and electron microscopic findings are indispensable for the pathological diagnosis of this condition. However, pathological findings become apparent in the form of nephritis progression, even in male XLAS cases or ARAS cases; for female XLAS and ADAS cases, typical findings of EM can be observed generally at later stages and often show only thinning of GBM. Therefore, careful observation is necessary, because there are cases with no obvious changes except for thin basement membrane (TBM) at the early stages of AS. Immunohistologically, specific findings can be identified with α5 staining. Approximately 80% of XLAS male patients are completely negative for α5 staining, while XLAS female patients exhibit a mosaic pattern due to the mechanisms of X-chromosome inactivation that occur in female cells (Fig. 2) [2, 16]. In ARAS patients, the GBM is negative for α3, α4, and α5 staining, while Bowman’s capsule is α5 positive; this is because the GBM consists of α3–α4–α5, but Bowman’s capsule consists of α5–α5–α6 and COL4A3/COL4A4 mutations do not influence α5 expression in Bowman’s capsule. In ADAS patients, both the GBM and Bowman’s capsule exhibit a normal pattern of α5 expression. α5 staining is a useful diagnostic method, because it remains unchanged regardless of age; however, it should solely be used as a method of auxiliary diagnosis, because it can show nonspecific findings, such as a normal expression pattern in more than 20% of XLAS males [1]. We have reported that 29% of male XLAS and 20% of ARAS cases showed atypical positive expression of α5 in GBM [12, 17]. All male XLAS cases with α5 positivity possessed non-truncating variants or somatic mosaic variants in COL4A5 and showed significantly milder phenotypes of later-onset ESRD [17]. ARAS cases with α5 positivity possessed a missense variant in at least one allele in the COL4A3 or COL4A4 gene and again showed a milder phenotype that involved later development of ESRD [12].

Fig. 1

Glomerular basement membrane (GBM) change in Alport syndrome (AS) observed by electron microscopy. A Thin basement membrane, which is typically observed in milder cases, including female X-linked AS and autosomal dominant AS. B Diffuse thickening and lamellation, which are specific findings of AS

Fig. 2

Immunohistochemical analysis of type IV collagen α5 chain in glomerulus. A Normal control shows full expression in both glomerular basement membrane (GBM) and Bowman’s capsule (BC). B Male X-linked Alport syndrome (XLAS) case shows completely negative expression in both GBM and BC. C Female XLAS case shows a mosaic pattern of expression in both GBM and BC due to the mechanisms of X-chromosome inactivation that occur in female cells. D Autosomal recessive Alport syndrome case shows negative expression only on GBM and positivity on BC, because BC consists of the α5–α5–α6 triple helix. E Schema for X-chromosome inactivation (XCI). In all female cells, either of the two X chromosomes is randomly inactivated. When the wild-type chromosome has been inactivated, the cell will not produce α5. Then, GBM and BC will be stained with a mosaic pattern

Skin basement membrane consists of type IV collagen α5–α5–α6 triple helix. Therefore, α5 staining is a useful auxiliary diagnostic method only for XLAS cases: male XLAS cases show negativity for α5 expression, while female XLAS cases show a mosaic expression pattern, as observed in GBM (Fig. 3A, B) [2]. It should be noted that decreased α5 expression can be observed at the bottom of the papillary epidermal basement membrane in normal skin (Fig. 3C, D) [18].

Fig. 3

Immunohistochemical analysis of type IV collagen α5 chain on epidermal basement membrane (EBM). A Male X-linked Alport syndrome (XLAS) case shows completely negative expression on EBM. B Female XLAS case shows a mosaic pattern of expression on EBM due to the mechanisms of X-chromosome inactivation that occur in female cells. C Normal control shows full α5 expression on EBM; however, decreased α5 expression can be observed in the bottom of papillary EBM in the normal skin. D Normal control shows full α2 expression on EBM, even at the bottom of papillary EBM

Gene tests

Along with the progression of gene analysis technology in recent years, there has been remarkable development of the genetic diagnosis system for AS. Because all three of the COL4A3, COL4A4, and COL4A5 genes consist of approximately 50 exons, conventional Sanger sequencing is too laborious and time-consuming for genetic screening. Therefore, the main strategy for gene screening in AS has become targeted sequencing, which captures all exons and exon–intron boundaries of all three genes, along with comprehensive sequencing analysis by NGS. Genes responsible for kidney diseases that clinically or pathologically resemble AS should be included in the targeted screening panel. For example, BOR syndrome shows nephritis and deafness; patients with these symptoms are sometimes suspected of having AS. Moreover, the pathological findings of Pierson syndrome frequently include lamellation of the GBM, as revealed by EM. Moreover, some cases of Pierson syndrome with missense variants in the LAMB2 gene tend to show milder phenotypes involving later onset of ESRD [19]. These clinical features resemble those of AS. Cases with gene variants in LMX1B (nail–patella syndrome), PAX2 (renal coloboma syndrome), or MYH9 (MYH9 nephropathy) also show lamellation of the GBM, so they should be included in the gene list. Most mutations detected in AS are novel variants, because there are no mutational hotspots among the three genes. When we fail to detect pathogenic variants by means of targeted sequencing, we must proceed to the next step of detecting copy number variations (CNVs) and deep intronic pathogenic variants. Our gene screening strategy for AS is as follows: Step 1: targeted next-generation sequencing with a custom disease panel; when pathogenic variants are detected, they are confirmed by Sanger sequencing. When we fail to detect mutations by Step 1, we proceed to Step 2, which involves conducting pair analysis comparing NGS data from patients and normal controls, to screen for CNVs. When pair analysis shows the possibility of CNVs in any of the three genes, we proceed to detecting CNVs by multiplex ligation-dependent probe amplification (MLPA). When we fail to detect pathogenic variants with Steps 1 and 2, we proceed to Step 3: reverse transcription–polymerase chain reaction (RT-PCR) of mRNA and direct sequencing to detect aberrant splicing due to intronic or exonic variants. With these three steps, we can detect pathogenic variants in any one gene for more than 90% of cases clinically suspected of being AS [7, 12, 14, 20]. With Step 2, we recently detected CNVs in COL4A5 in AS cases [21]. Pair analysis also revealed a case with clinically suspected AS because of ESRD and hearing loss, which had CNVs in the EYA1 gene, and diagnosed this as BOR syndrome [21]. With Step 3, we have identified deep intronic variants that lead to cryptic exon insertion by creating novel splicing sites [12, 20]. We have also identified aberrant splicing caused by a so-called “silent variant,” an exonic single-nucleotide substitution that does not change the coding amino acid [22].

Genotype–phenotype correlation

Three reports have been published analyzing the correlation between genotype and clinical picture based on large-scale data in male XLAS patients; we briefly summarize them here.

  1. 1.

    In 2000, Jais et al. analyzed 401 male XLAS patients from 195 families. The results showed that the median age at developing ESRD overall was 25 years; 90% of patients had developed ESRD by the age of 40. Genetically, the frequencies of progression to ESRD by the age of 30 were (1) 90% in cases with wide deletions, nonsense mutations, or frameshift mutations; (2) 70% in cases with splice site mutations; and (3) 50% in cases with missense mutations. This report showed for the first time that the kidney prognosis differed significantly depending on mutation type [8].

  2. 2.

    In 2002, Gross et al. conducted a meta-analysis of 267 men with XLAS, including cases that had been previously reported. They classified genetic mutations into the following three groups and evaluated their renal prognosis: (1) large rearrangements, premature stops, frameshift mutations, mutations of splice donor sites, or mutations in the NC domain (truncated protein group) were associated with the development of ESRD at the median age of 19.8 years; (2) missense mutations of glycine in exons 21–47, in-frame mutations, and mutations involving the splicing acceptor site (altered protein structure group) were associated with the development of ESRD at the median age of 25.7 years; and (3) missense mutations of glycine of exons 1–20 were associated with the development of ESRD at the median age of 30.1 years [23].

  3. 3.

    In 2010, Bekheirnia et al. analyzed 681 male patients with XLAS from 175 families. The results were as follows: The median age of developing ESRD was (1) 37 years with missense mutations, (2) 28 years with splice site mutations, (3) 25 years with truncating mutations, and (4) 22 years with both large- and small-deletion mutations. Furthermore, the position of mutations closer to the 5′ end tended to show earlier progression of ESRD; in the same analysis, limited to only missense mutations in glycine, there was no correlation between location and severity. In these respects, the results differed from those in the report by Gross et al. [24].

Regarding female XLAS cases, two previous reports showed no genotype–phenotype correlations [7, 9]. It has long been suspected that an uneven pattern of X-chromosome inactivation (i.e., skewed X chromosome inactivation) would influence the severity of XLAS in females [25]; however, no study has systematically proven the correlation between a skewed X pattern and clinical severity in female XLAS. In our experience, X-chromosome inactivation pattern analysis cannot predict kidney prognosis in female XLAS cases (manuscript in preparation).

For ARAS, two previous reports discussed the genotype–phenotype correlation in this condition.

  1. 1.

    In 2013, Storey et al. reported that patients with truncating mutations in at least one allele tended to show early onset of renal failure, compared with patients without truncating mutations [13].

  2. 2.

    In 2014, Oka et al. (our group) reported that no genotype–phenotype correlation was observed in ARAS cases, even when the patients were divided into two groups, similar to those of Storey et al. However, some cases that exhibited missense mutations in at least one allele showed milder phenotypes, with full expression of α5 on GBM [12].

In ADAS, no genotype–phenotype correlations have been observed thus far. Even within one family, clinical severity differed significantly and some individuals developed ESRD, whereas others possessing the same mutation showed no urinary abnormality [14].

Mechanisms of onset of atypical mild phenotypes in male XLAS

It has been reported that some male XLAS cases show atypical mild phenotypes of late-onset ESRD. Based on previously reported results, it has been clarified that, for the following reasons, XLAS male patients may exhibit a mild clinical picture.

  1. 1.

    Cases with missense mutations

In all large-scale studies that analyzed genotype–phenotype correlations, it was reported that the age at which ESRD developed was significantly delayed in cases possessing missense mutations, as described above [8, 23, 24]. We have reported a male patient with very mild XLAS who had a missense mutation (p.Gly1000Val) in the COL4A5 gene and only showed hematuria at the age of 38 years [26]. We have also encountered a 40-year-old male with the same mutation who only showed hematuria (unpublished data). Thus, some missense mutations can lead to extremely mild phenotypes.

  1. 2.

    Cases with in-frame deletion mutations

For mutations involving deletion of a multiple of three nucleotides, the fact that three bases code one amino acid means that this mutation does not significantly influence the subsequent amino acid sequence (i.e., no frameshift occurs). Such mutations are called in-frame deletion mutations. Gross et al. reported that, when an in-frame mutation occurs, the age at which ESRD develops is significantly later than in cases with frameshift mutations [23]. In addition, Jais et al. classified in-frame deletions with deleted nucleotides numbering from 3 to 18 bases into a missense mutation group and analyzed them, because they showed mild phenotypes [8]. We also have reported two families with mild disease phenotypes, the members of which progressed to end-stage renal failure in their 60 s and 40 s due to deletions of 9 and 36 bases, respectively [17].

  1. 3.

    Cases with splice site mutations result in in-frame deletion at the transcript level

Furthermore, we recently reported a male with a deletion of 105 bases at the mRNA level due to a splice site mutation, in whom ESRD had not developed at the age of 47 [20]. This case showed an in-frame mutation at the mRNA level, indicating that mutation at a splice site may be associated with a mild clinical picture. Recently, we published the results of a large data analysis comparing splice site mutations, with or without in-frame deletion, at the transcript levels; we revealed that renal prognosis differs significantly, and that ESRD developed 9 years later in the in-frame deletion group [27].

  1. 4.

    Somatic cell mosaicism in proband cases

Mosaic mutations involve the presence of two cell populations with different genotypes in one individual, which have developed from a single fertilized egg (Fig. 4). Probands in cases of hereditary diseases can sometimes develop to retain mutants at somatic cell division failure. When this gene mutation is inserted after repeated cell division in fertilized eggs, cells with a normal gene and cells with an abnormal gene coexist; this is known as mosaicism. When this status is observed among somatic cells, it is recognized as somatic mosaicism. We previously reported a male patient with mild XLAS who had a mutation with somatic mosaicism [28]. Recently, we reported a tendency for an association between variant allele frequency and severity of renal symptoms in four men with XLAS with somatic mosaic variants [29]. Variant allele frequency was analyzed by ultra-deep sequencing with NGS. One of the cases, whose two daughters exhibited typical findings of female XLAS, was completely asymptomatic.

Fig. 4

Schema of genetic mosaicism. When gene mutation occurs after repeated cycles of cell division in fertilized eggs, cells with a normal gene and cells with an abnormal gene coexist; this is known as mosaicism. When this status occurs in somatic cells, it is recognized as somatic mosaicism; in gonadal cells, it is known as germline mosaicism

  1. 5.

    A case with splice site mutation, in which both normal mRNA and aberrantly spliced mRNA are produced in renal tissue during transcription

With splice site mutations, exon skipping is usually observed. However, incomplete mutation of the splice site may produce both normal and abnormal kidney mRNA, leading to milder phenotypes. This mechanism has been reported in another inherited disease, galactosialidosis [30]. In this disease, the IVS8 + 9C > G variant in the CTSA gene produces abnormally spliced mRNA with a low level of normal mRNA, which leads to a milder phenotype in the patient. A similar mechanism was also observed in a male XLAS case with a mild phenotype. We recently reported a mild XLAS case that exhibited only hematuria and very mild proteinuria despite being 22 years; the patient possessed a deep intronic mutation that produced both normal and abnormal mRNA in the kidney [20].

  1. 6.

    Cases with α5 expression in GBM

In a typical XLAS male patient, because of abnormality of the COL4A5 gene, expression of α5 is not recognized at all in GBM. However, the expression of α5 was confirmed in 29% of male XLAS patients; in those α5-positive cases, it was found that the age at which urinary protein was exhibited was significantly older, the amount of urine protein was significantly lower, the age of end-stage renal failure was also significantly older (37 years vs. 24 years), and the rate of hearing loss was also significantly lower. Thus, it was shown that α5-positive cases may exhibit a mild clinical picture [17]. Similar results were also recently published by a different group [31]. These cases with α5-positive expression in GBM possessed non-truncating (missense or in-frame deletion) mutations or somatic mosaic mutations in COL4A5 [17].


There is currently no radical therapy for AS; treatment is only performed for the purpose of delaying progression to renal failure using nephroprotective drugs. A randomized controlled trial (RCT) is underway in Germany (EARLY PRO-TECT ALPORT study) for confirming nephroprotective effects. Two RCT trial results have been previously published examining reduction of urine protein levels by angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in AS [32, 33]. One compared losartan (ARB) and placebo, while another compared enalapril (ACEI) and losartan; both RCTs showed urine protein-reducing effects in both ACEI and ARB. A large retrospective study reported that ACEIs have the effect of delaying the progression to ESRD in AS [34]. Recently published expert guidelines recommend that male patients initiate treatment with ACEI from the time of diagnosis with AS [35]. Meanwhile, in female cases, it is recommended to start treatment at the time when urinary protein is detected, in addition to urine occult blood [35]. For ARAS, ACEI should be started at the time of diagnosis regardless of gender and, for ADAS, it should be initiated at the time when urinary protein is detected. No clinical trial has been performed comparing single (ACEI or ARB) and double block (ACEI and ARB); theoretically, double block can show a stronger renoprotective effect, and is already applied in clinical settings. It was previously reported that cyclosporine treatment for AS significantly reduced urine protein levels and showed renoprotective effects in long-term follow-up [36, 37]. However, three recent reports showed that, although cyclosporine had strong effects for reducing urine protein, it accelerated interstitial fibrosis and had no renoprotective effects [38,39,40].

Regarding kidney transplantation, good results have been obtained compared with those in other kidney diseases; however, in 2–5% of cases, anti-GBM antibody is produced, leading to rapid graft loss [41]. There is no curative therapy for hearing impairment; only symptomatic treatment is available, such as the use of a hearing aid.

Some new drugs have entered clinical trials, such as bardoxolone methyl (Phase II/III) and RG-012 (effect on microRNA-21 interference, Phase II). Other therapies that have thus far been reported to show effects by in vivo and in vitro trials are as follows: (1) treatment with stem cells [42] and (2) treatment to control intracellular signal transduction (USAG-1) [43]. Further expected treatments are as follows: (1) nonsense read-through therapy [44] and (2) exon skipping therapy with antisense oligonucleotides or chemical compounds [45, 46]. Notably, our group is working to develop exon skipping therapy using antisense oligonucleotide (ASO). ASO will bind to the exonic splicing enhancer region and disturb the targeted exon at the point of splicing; this will lead to exon skipping. As described above, when the skipped exon nucleotide number is a multiple of 3, it change the severe phenotype with nonsense mutation to a milder phenotype with an in-frame deletion. We have already obtained good results in vitro and are proceeding to an in vivo trial with an animal model.

The border between TBM and AS

An issue of particular interest among experts in the field of AS is the differential diagnosis between AS and TBM. AS has generally been defined as progressive nephritis, sensorineural hearing loss, and specific eye abnormalities; TBM is generally defined as hematuria with/without mild proteinuria, with diffuse thinning of GBM that does not result in renal failure. There remains no clear delineation between the two diseases and leading clinical nephrologists are quite confused. Most heterozygous carriers of variants in COL4A3 or COL4A4 or some females with heterozygous mutations in COL4A5 show only hematuria without proteinuria; those cases are not diagnosed with AS, according to its current definition. It is well-known that most cases with benign familial hematuria possess heterozygous mutations in either COL4A3 or COL4A4, and most will not develop ESRD [47]. It is also well-known that, in cases with only hematuria without proteinuria, ESRD will never develop [9]. In EM findings, these cases typically show only TBM without lamellation of the lamina densa [7, 14]. In contrast, cases with ADAS begin to show proteinuria at the median age of 17 years; for females with XLAS, the equivalent age is 7 years. These findings indicate that there is no clear distinction between these two diseases, which presents difficulties for physicians when attempting to make a differential diagnosis. We have experienced some cases exhibiting only hematuria at a young age, which were diagnosed with TBM; these patients then missed annual check-ups and developed ESRD at approximately 60 years of age (personal experience). ACEI can delay the age of developing ESRD, even in male cases of XLAS with the most severe phenotype. This indicates that ACEI can remarkably delay the age of ESRD development for cases with much milder phenotypes of ADAS. As experts in this field, we are responsible for ensuring that, in AS cases, the opportunity to begin treatment by ACEI is not missed. Diagnosis of TBM tends to underestimate the risk of progressive kidney disease. Therefore, some experts have recently asserted that patients with hematuria, TBM, and heterozygous mutations in COL4A3 or COL4A4 should be classified as cases of autosomal AS. In addition, all females with XLAS should also be classified as cases of XLAS. These changes of definition of AS may eliminate TBM nephropathy as a diagnostic entity [48].


Recent advances in genetic analysis have provided us with a deeper understanding of the pathophysiological mechanisms of inherited kidney diseases. Based on precise genetic information, we came to understand the mechanisms of onset of milder phenotypes in AS. As experts in this field, we must devote our energies to creating a system that allows patients with AS to be diagnosed at an early stage and to start appropriate treatment. For this reason, we need to change the definition of AS to include all cases with nephropathy caused by COL4A3, COL4A4, or COL4A5 gene variants and eliminate the disease entity of TBM; this will allow patients to avoid missing the opportunity to start appropriate treatment as early as possible.


  1. 1.

    Kashtan CE. Alport syndrome. An inherited disorder of renal, ocular, and cochlear basement membranes. Medicine (Baltimore). 1999;78(5):338–60.

    CAS  Article  Google Scholar 

  2. 2.

    Nakanishi K, Yoshikawa N, Iijima K, Kitagawa K, Nakamura H, Ito H, et al. Immunohistochemical study of alpha 1–5 chains of type IV collagen in hereditary nephritis. Kidney Int. 1994;46(5):1413–21.

    CAS  Article  Google Scholar 

  3. 3.

    Rheault MN, Kashtan CE. Inherited glomerular diseases. Ped Nephrol. 2016; 7 1918–84.

    Google Scholar 

  4. 4.

    Mallett A, Tang W, Clayton PA, Stevenson S, McDonald SP, Hawley CM, et al. End-stage kidney disease due to Alport syndrome: outcomes in 296 consecutive Australia and New Zealand dialysis and transplant registry cases. Nephrol Dial Transplant. 2014;29(12):2277–86. https://doi.org/10.1093/ndt/gfu254.

    Article  PubMed  Google Scholar 

  5. 5.

    Hattori M, Sako M, Kaneko T, Ashida A, Matsunaga A, Igarashi T, et al. End-stage renal disease in Japanese children: a nationwide survey during 2006–2011. Clin Exp Nephrol. 2015;19(5):933–8. https://doi.org/10.1007/s10157-014-1077-8.

    Article  Google Scholar 

  6. 6.

    Nakanishi K, Yoshikawa N. Alport syndrome. Nihon Jinzo Gakkai Shi. 2015;57(4):736–42.

    CAS  PubMed  Google Scholar 

  7. 7.

    Yamamura T, Nozu K, Fu XJ, Nozu Y, Ye MJ, Shono A, et al. Natural history and genotype-phenotype correlation in female x-linked alport syndrome. Kidney Int Rep. 2017;2(5):850–5. https://doi.org/10.1016/j.ekir.2017.04.011.

    Article  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, et al. X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol. 2000;11(4):649–57.

    CAS  Google Scholar 

  9. 9.

    Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a “European Community Alport Syndrome Concerted Action” study. J Am Soc Nephrol. 2003;14(10):2603–10.

    Article  Google Scholar 

  10. 10.

    Savige J, Sheth S, Leys A, Nicholson A, Mack HG, Colville D. Ocular features in Alport syndrome: pathogenesis and clinical significance. Clin J Am Soc Nephrol. 2015;10(4):703–9. https://doi.org/10.2215/CJN.10581014.

    Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Nozu K, Minamikawa S, Yamada S, Oka M, Yanagita M, Morisada N, et al. Characterization of contiguous gene deletions in COL4A6 and COL4A5 in Alport syndrome-diffuse leiomyomatosis. J Hum Genet. 2017;62(7):733–5. https://doi.org/10.1038/jhg.2017.28.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Oka M, Nozu K, Kaito H, Fu XJ, Nakanishi K, Hashimura Y, et al. Natural history of genetically proven autosomal recessive Alport syndrome. Pediatr Nephrol. 2014;29(9):1535–44. https://doi.org/10.1007/s00467-014-2797-4.

    Article  PubMed  Google Scholar 

  13. 13.

    Storey H, Savige J, Sivakumar V, Abbs S, Flinter FA. COL4A3/COL4A4 mutations and features in individuals with autosomal recessive Alport syndrome. J Am Soc Nephrol. 2013;24(12):1945–54. https://doi.org/10.1681/ASN.2012100985.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Kamiyoshi N, Nozu K, Fu XJ, Morisada N, Nozu Y, Ye MJ, et al. Genetic, clinical, and pathologic backgrounds of patients with autosomal dominant Alport syndrome. Clin J Am Soc Nephrol. 2016;11(8):1441–9. https://doi.org/10.2215/CJN.01000116.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Malone AF, Phelan PJ, Hall G, Cetincelik U, Homstad A, Alonso AS, et al. Rare hereditary COL4A3/COL4A4 variants may be mistaken for familial focal segmental glomerulosclerosis. Kidney Int. 2014;86(6):1253–9. https://doi.org/10.1038/ki.2014.305.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Nakanishi K, Iijima K, Kuroda N, Inoue Y, Sado Y, Nakamura H, et al. Comparison of alpha5(IV) collagen chain expression in skin with disease severity in women with X-linked Alport syndrome. J Am Soc Nephrol. 1998;9(8):1433–40.

    CAS  PubMed  Google Scholar 

  17. 17.

    Hashimura Y, Nozu K, Kaito H, Nakanishi K, Fu XJ, Ohtsubo H, et al. Milder clinical aspects of X-linked Alport syndrome in men positive for the collagen IV alpha5 chain. Kidney Int. 2014;85(5):1208–13. https://doi.org/10.1038/ki.2013.479.

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Patey-Mariaud de Serre N, Garfa M, Bessieres B, Noel LH, Knebelmann B. Collagen alpha5 and alpha2(IV) chain coexpression: analysis of skin biopsies of Alport patients. Kidney Int. 2007;72(4):512–6. https://doi.org/10.1038/sj.ki.5002365.

    CAS  Article  Google Scholar 

  19. 19.

    Matejas V, Hinkes B, Alkandari F, Al-Gazali L, Annexstad E, Aytac MB, et al. Mutations in the human laminin beta2 (LAMB2) gene and the associated phenotypic spectrum. Hum Mutat. 2010;31(9):992–1002. https://doi.org/10.1002/humu.21304.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Nozu K, Vorechovsky I, Kaito H, Fu XJ, Nakanishi K, Hashimura Y, et al. X-linked Alport syndrome caused by splicing mutations in COL4A5. Clin J Am Soc Nephrol. 2014;9(11):1958–64. https://doi.org/10.2215/CJN.04140414.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  21. 21.

    Nagano C, Nozu K, Morisada N, Yazawa M, Ichikawa D, Numasawa K, et al. Detection of copy number variations by pair analysis using next-generation sequencing data in inherited kidney diseases. Clin Exp Nephrol. 2018. https://doi.org/10.1007/s10157-018-1534-x.

    Article  PubMed  Google Scholar 

  22. 22.

    Fu XJ, Nozu K, Eguchi A, Nozu Y, Morisada N, Shono A, et al. X-linked Alport syndrome associated with a synonymous p.Gly292Gly mutation alters the splicing donor site of the type IV collagen alpha chain 5 gene. Clin Exp Nephrol. 2016;20(5):699–702. https://doi.org/10.1007/s10157-015-1197-9.

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Gross O, Netzer KO, Lambrecht R, Seibold S, Weber M. Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling. Nephrol Dial Transplant. 2002;17(7):1218–27.

    Article  Google Scholar 

  24. 24.

    Bekheirnia MR, Reed B, Gregory MC, McFann K, Shamshirsaz AA, Masoumi A, et al. Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol. 2010;21(5):876–83. https://doi.org/10.1681/ASN.2009070784.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Migeon BR. X inactivation, female mosaicism, and sex differences in renal diseases. J Am Soc Nephrol. 2008;19(11):2052–9. https://doi.org/10.1681/ASN.2008020198.

    Article  PubMed  Google Scholar 

  26. 26.

    Kaneko K, Tanaka S, Hasui M, Nozu K, Krol RP, Iijima K, et al. A family with X-linked benign familial hematuria. Pediatr Nephrol. 2010;25(3):545–8. https://doi.org/10.1007/s00467-009-1370-z.

    Article  PubMed  Google Scholar 

  27. 27.

    Horinouchi T, Nozu K, Yamamura T, Minamikawa S, Omori T, Nakanishi K, et al. Detection of splicing abnormalities and genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol. 2018. https://doi.org/10.1681/ASN.2018030228.

    Article  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Krol RP, Nozu K, Nakanishi K, Iijima K, Takeshima Y, Fu XJ, et al. Somatic mosaicism for a mutation of the COL4A5 gene is a cause of mild phenotype male Alport syndrome. Nephrol Dial Transplant. 2008;23(8):2525–30. https://doi.org/10.1093/ndt/gfn005.

    CAS  Article  Google Scholar 

  29. 29.

    Fu XJ, Nozu K, Kaito H, Ninchoji T, Morisada N, Nakanishi K, et al. Somatic mosaicism and variant frequency detected by next-generation sequencing in X-linked Alport syndrome. Eur J Hum Genet. 2016;24(3):387–91. https://doi.org/10.1038/ejhg.2015.113.

    CAS  Article  Google Scholar 

  30. 30.

    Richard C, Tranchemontagne J, Elsliger MA, Mitchell GA, Potier M, Pshezhetsky AV. Molecular pathology of galactosialidosis in a patient affected with two new frameshift mutations in the cathepsin A/protective protein gene. Hum Mutat. 1998;11(6):461–9. https://doi.org/10.1002/(SICI)1098-1004(1998)11:6%3C461::AID-HUMU7%3E3.0.CO;2-F.

    CAS  Article  PubMed  Google Scholar 

  31. 31.

    Said SM, Fidler ME, Valeri AM, McCann B, Fiedler W, Cornell LD, et al. Negative staining for COL4A5 correlates with worse prognosis and more severe ultrastructural alterations in males with Alport syndrome. Kidney Int Rep. 2017;2(1):44–52. https://doi.org/10.1016/j.ekir.2016.09.056.

    Article  PubMed  Google Scholar 

  32. 32.

    Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, McCrary Sisk C, et al. Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome. Pediatr Nephrol. 2013;28(5):737–43. https://doi.org/10.1007/s00467-012-2372-9.

    Article  PubMed  Google Scholar 

  33. 33.

    Webb NJ, Lam C, Shahinfar S, Strehlau J, Wells TG, Gleim GW, et al. Efficacy and safety of losartan in children with Alport syndrome–results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. Nephrol Dial Transplant. 2011;26(8):2521–6. https://doi.org/10.1093/ndt/gfq797.

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Gross O, Licht C, Anders HJ, Hoppe B, Beck B, Tonshoff B, et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int. 2012;81(5):494–501. https://doi.org/10.1038/ki.2011.407.

    CAS  Article  Google Scholar 

  35. 35.

    Savige J, Gregory M, Gross O, Kashtan C, Ding J, Flinter F. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol. 2013;24(3):364–75. https://doi.org/10.1681/ASN.2012020148.

    CAS  Article  Google Scholar 

  36. 36.

    Callis L, Vila A, Carrera M, Nieto J. Long-term effects of cyclosporine A in Alport’s syndrome. Kidney Int. 1999;55(3):1051–6. https://doi.org/10.1046/j.1523-1755.1999.0550031051.x.

    CAS  Article  PubMed  Google Scholar 

  37. 37.

    Callis L, Vila A, Nieto J, Fortuny G. Effect of cyclosporin A on proteinuria in patients with Alport’s syndrome. Pediatr Nephrol. 1992;6(2):140–4.

    CAS  Article  Google Scholar 

  38. 38.

    Sugimoto K, Fujita S, Miyazawa T, Nishi H, Enya T, Izu A, et al. Cyclosporin A may cause injury to undifferentiated glomeruli persisting in patients with Alport syndrome. Clin Exp Nephrol. 2014;18(3):492–8. https://doi.org/10.1007/s10157-013-0836-2.

    CAS  Article  PubMed  Google Scholar 

  39. 39.

    Massella L, Muda AO, Legato A, Di Zazzo G, Giannakakis K, Emma F. Cyclosporine A treatment in patients with Alport syndrome: a single-center experience. Pediatr Nephrol. 2010;25(7):1269–75. https://doi.org/10.1007/s00467-010-1484-3.

    Article  PubMed  Google Scholar 

  40. 40.

    Charbit M, Gubler MC, Dechaux M, Gagnadoux MF, Grunfeld JP, Niaudet P. Cyclosporin therapy in patients with Alport syndrome. Pediatr Nephrol. 2007;22(1):57–63. https://doi.org/10.1007/s00467-006-0227-y.

    Article  PubMed  Google Scholar 

  41. 41.

    Kashtan CE. Renal transplantation in patients with Alport syndrome. Pediatr Transplant. 2006;10(6):651–7. https://doi.org/10.1111/j.1399-3046.2006.00528.x.

    Article  PubMed  Google Scholar 

  42. 42.

    Moschidou D, Corcelli M, Hau KL, Ekwalla VJ, Behmoaras JV, De Coppi P, et al. Human chorionic stem cells: podocyte differentiation and potential for the treatment of Alport syndrome. Stem Cells Dev. 2016;25(5):395–404. https://doi.org/10.1089/scd.2015.0305.

    CAS  Article  PubMed  Google Scholar 

  43. 43.

    Tanaka M, Asada M, Higashi AY, Nakamura J, Oguchi A, Tomita M, et al. Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome. J Clin Invest. 2010;120(3):768–77. https://doi.org/10.1172/JCI39569.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Peltz SW, Morsy M, Welch EM, Jacobson A. Ataluren as an agent for therapeutic nonsense suppression. Annu Rev Med. 2013;64:407–25. https://doi.org/10.1146/annurev-med-120611-144851.

    CAS  Article  PubMed  Google Scholar 

  45. 45.

    Evers MM, Toonen LJ, van Roon-Mom WM. Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev. 2015;87:90–103. https://doi.org/10.1016/j.addr.2015.03.008.

    CAS  Article  PubMed  Google Scholar 

  46. 46.

    Kataoka N. Modulation of aberrant splicing in human RNA diseases by chemical compounds. Hum Genet. 2017;136(9):1237–45. https://doi.org/10.1007/s00439-017-1789-4.

    CAS  Article  Google Scholar 

  47. 47.

    Wang YY, Rana K, Tonna S, Lin T, Sin L, Savige J. COL4A3 mutations and their clinical consequences in thin basement membrane nephropathy (TBMN). Kidney Int. 2004;65(3):786–90. https://doi.org/10.1111/j.1523-1755.2004.00453.x.

    CAS  Article  Google Scholar 

  48. 48.

    Kashtan CE, Ding J, Garosi G, Heidet L, Massella L, Nakanishi K, et al. Alport syndrome: a unified classification of genetic disorders of collagen IV alpha345: a position paper of the Alport Syndrome Classification Working Group. Kidney Int. 2018. https://doi.org/10.1016/j.kint.2017.12.018.

    Article  PubMed  Google Scholar 

Download references


We thank Colleen Elso, PhD, and Ryan Chastain-Gross, PhD, from Edanz Group (http://www.edanzediting.com/ac) for editing a draft of this manuscript.


This study was supported by a grant from the Ministry of Health, Labour and Welfare of Japan for Research on Rare Intractable Diseases in the Kidney and Urinary Tract [H24-nanchitou (nan)-ippan-041 to Kazumoto Iijima] in the “Research on Measures for Intractable Diseases” Project, Grants-in-Aid for Scientific Research (KAKENHI) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (subject ID: 15K09691 to Kandai Nozu and 17H04189 to Kazumoto Iijima), and a Grant from the Japan Agency for Medical Research and Development, AMED (subject ID: 7930006 to Kandai Nozu).

Author information




As members of the Working Group for Alport Syndrome in the Japanese Society of Pediatric Nephrology, all coauthors contributed this review article as follows. SO, TU, and AK wrote the section of “Clinical characteristics and diagnostic features.” YA, TY, and SM wrote the section of “Treatment.” ET, TH, RF, HK, and KT wrote the section of genotype–phenotype correlation. KK, TO, and N.Y. wrote the section of “the mechanisms of onset of atypical mild phenotypes in male XLAS.” KN, TH, and SM wrote the section of “pathological findings” and “Gene test.” KN translated all manuscripts to English and made modifications for the review article. KI and MN critically reviewed the manuscript. All authors read and approved the final version of the manuscript.

Corresponding author

Correspondence to Kandai Nozu.

Ethics declarations

Conflict of interest

Kazumoto Iijima has received grant support from Daiichi Sankyo Co. Ltd. He has also received consulting fees from Takeda Pharmaceutical Company and Kyowa Hakko Kirin Co. Ltd. Kandai Nozu has received lecture fees from Novartis Pharmaceuticals Corporation. Kazumoto Iijima and Kandai Nozu have filed a patent application on the development of antisense nucleotides for exon skipping therapy in Alport syndrome. The remaining authors have declared that no conflict of interest exists.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was not required, as this study did not involve human participants.

Additional information

This article was presented as the Clinical Scientist Award memorial lecture at the 60th annual meeting of the Japanese Society of Nephrology, held at Sendai, Japan in 2017.

Rights and permissions

This article is published under an open access license. Please check the 'Copyright Information' section for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nozu, K., Nakanishi, K., Abe, Y. et al. A review of clinical characteristics and genetic backgrounds in Alport syndrome. Clin Exp Nephrol 23, 158–168 (2019). https://doi.org/10.1007/s10157-018-1629-4

Download citation


  • Genotype–phenotype correlation
  • Thin basement membrane
  • ACE inhibitor
  • Bardoxolone